The use of antidepressants in novel combination therapies.
Antidepressant monotherapy is used more often than other therapies to achieve symptom remission in depressed patients; however, for patients resistant to antidepressants, other strategies are necessary. Many novel combination therapies have been proposed to treat resistant depression. The efficacy of combination therapies such as lithium augmentation of antidepressants is supported by a large amount of evidence including data from controlled trials. Nonetheless, anecdotal reports suggest that these combinations are underutilized. Data from studies of the use of the combination of atypical antipsychotics and selective serotonin reuptake inhibitors suggest that this is a particularly promising therapeutic avenue. However, more research is needed to corroborate these early results.
Shelton
Richard C
RC
Adult Psychiatry Division, Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212-8646, USA. richard.shelton@vanderbilt.edu
D000465:Algorithms; D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D004359:Drug Therapy, Combination; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome; D014284:Triiodothyronine / Q000627:therapeutic use
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D008094:Lithium; D017367:Selective Serotonin Reuptake Inhibitors; D014284:Triiodothyronine